Dr. Ng Ting Ying - Clinical Oncology
Specialist in Clinical Oncology
Highlights
- MCHK RegisteredVerified
- Specialist in Clinical OncologyBachelor of Medicine and Bachelor of Surgery (MBBS) · Hong Kong College of Radiologists · Medical degree 1993
- InsuranceBeing compiled｜See details
About
Dr. Ng Ting Ying is a registered Clinical Oncology specialist in Hong Kong.
Education
Specialist in Clinical Oncology
- Bachelor of Medicine and Bachelor of Surgery (MBBS)Bachelor of Medicine and Bachelor of Surgery (MBBS)1993
Hong Kong Academy of Medicine fellowships
- FHKCRFellow, Hong Kong College of Radiologists
Source: Hong Kong Academy of Medicine Fellows Register, checked 12 Sep 2026
Insurance
Insurance plans being compiled
We're collecting insurance plan data per clinic. For confirmation, contact the clinic directly.
Are you Dr. Ng Ting Ying? Claim page and update insurance →
FAQ
Is Dr. Ng Ting Ying any good?
Dr. Ng Ting Ying is a registered Clinical Oncology specialist in Hong Kong. Qualifications and registration come from the Hong Kong Medical Council. ok.med does not rate or rank doctors.
What does Dr. Ng Ting Ying do?
Dr. Ng Ting Ying practises in Clinical Oncology.
Are you Dr. Ng Ting Ying? Claim this page to update and manage.
ClaimResearch and publications
12 papers
Filter by paper topic
Topics come from medical classifications on these PubMed papers, not from the doctor's listed services.
- Real-world evidence of mammography screening from the Hong Kong Breast Cancer Registry: a cost minimisation analysis of 15 144 patients with breast cancer.BMJ public health · 2026
- Real-world use of neratinib as extended adjuvant therapy in HER2-positive early-stage breast cancer: a multicentre study in mainland China and Hong Kong.Breast (Edinburgh, Scotland) · 2026
- Modifiable Risk Factors Including Self-Perceived Stress for Breast Cancer in Hong Kong: A Case-Control Study of 10 757 Subject.Clinical Medicine Insights. Oncology · 2025
- Knowledge, attitudes and intention on fertility preservation among breast cancer patients.Scientific reports · 2023
- Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.Breast cancer research and treatment · 2021
- Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study.Breast cancer research and treatment · 2021
- Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis.BMC cancer · 2019
- BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy.Cancer research and treatment · 2019
- A young man with a mass on the neck.BMJ (Clinical research ed.) · 2018
- Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1.Breast cancer research : BCR · 2017
- Aspirin and risk of multiple myeloma in adults: A systematic review and meta-analysis.Leukemia research reports · 2017
- Clinical features and treatment outcomes of Hodgkin's lymphoma in Hong Kong Chinese.Archives of medical science : AMS · 2014
Publication data comes from PubMed / Europe PMC and is matched automatically by name and affiliation. Every entry links to the source.
For reference only. Not medical advice. Read full disclaimer